'Company Overview
Company Type: Public Company
Website: www.sqidiagnostics.com
Number of Employees: 42
Ticker: SQD (TSXV)
Year Founded: 1999


Business Description
SQI Diagnostics Inc., a precision medicine company, discovers, develops, and commercializes rapid diagnostic testing services for healthcare providers, patients, and consumers worldwide. The company also offers TOR-dx, a lung test, which enables the surgeon to assess the health of the donor's lung; and a COVID-19 at-home antibody test kit; the RALI-Dx, a COVID-19 severity triage lab test; and RALI-fast, a COVID-19 severity triage POC test. In addition, it offers microarray tests for protein and antibody testing workflow. The company was founded in 1999 and is headquartered in Toronto, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
3.0
Market Capitalization
6.1
TEV/Total Revenue
6.8x
EBITDA
(9.6)
Total Enterprise Value
20.8
TEV/EBITDA
NM
EBIT
(12.7)
Cash & ST Invst.
0.6
P/Diluted EPS Before Extra
NM
Net Income
(19.1)
Total Debt
15.2
Price/Tang BV
NM
Capital Expenditure
(0.4)
Total Assets
3.9
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Mar-31-2023 TEV and Market Cap are calculated using a close price as of Jun-14-2023

Key Professionals
Name
Title
Morris, Andrew 
Advisor to the Board & CEO
Lea, Peter
Founder
Reddock, Morlan 
CFO & VP of Administration
Brouwer, Eric 
Chief Scientific Officer & Advisor to the Board
McGough, Tim 
Chief Commercial Officer

Key Board Members
Name
Title
Beddoe, Clive J.
Independent Chairman of the Board
Ricks, Claude 
Independent Director
Shoenfeld, Yehuda 
Chairman of Scientific Advisory Board
Connor, Gerald R.
Independent Director
Matthews, Wilmot Leslie
Independent Director
Zwisler, Eric 
Independent Director


Primary Industry Classification
Health Care Equipment


Primary Office Location
36 Meteor Drive | Toronto, ON | M9W 1A4 | Canada
Fax: 416 674 9500

Current and Pending Investors
Cumberland Asset Management, Federal Economic Development Agency for Southern Ontario, Focus Asset Management Limited, NWM Mining Corporation

Prior Investors
Hanover Investors Management LLP, Pinetree Capital Ltd. (TSX:PNP)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Emblem Capital Inc.
As of April 20, 2007, Emblem Capital Inc. was acquired by Umedik, Inc in a reverse merger transaction. Emblem Capital, Inc., a capital pool company, does not have significant operations. It intends to acquire a biotechnology company that has developed and patented a micro array diagnostic technology that miniaturizes the capabilities of reference-lab analyzers into a desktop-sized device. The company was incorporated in 2003 and is based in Toronto, Canada.

United States and Canada
Asset Management and Custody Banks
-
1.00
0.00
SQI Diagnostics Systems Inc

United States and Canada
-
-
-
-
SQI US, Inc.

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Nov-24-2022
Dec-16-2022
Private Placement
Target
SQI Diagnostics Inc. (TSXV:SQD)


0.84
Nov-10-2022
-
Private Placement
Target
SQI Diagnostics Inc. (TSXV:SQD)
Federal Economic Development Agency for Southern Ontario

1.50
Jun-17-2022
Jun-17-2022
Private Placement
Target
SQI Diagnostics Inc. (TSXV:SQD)


3.10
Sep-24-2021
Nov-08-2021
Private Placement
Target
SQI Diagnostics Inc. (TSXV:SQD)


7.72
Jan-31-2020
Mar-05-2020
Private Placement
Target
SQI Diagnostics Inc. (TSXV:SQD)


2.98
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jun-30-2023
Annual General Meeting
SQI Diagnostics Inc., Annual General Meeting, Jun 30, 2023
Jun-16-2023
Delistings
SQI Diagnostics Expects its Common Shares to Continue to be Halted from Trading on Exchange and Ultimately Suspended and Delisted Following Completion of the Filing
Jun-16-2023
Debt Defaults
SQI Diagnostics Announces Receipt of Intention to Enforce Security from Pivot Financial and Anticipated Voluntary Bankruptcy Filing
Jun-06-2023
Executive/Board Changes - Other
SQI Diagnostics Inc. Announces Executive Changes
Jun-02-2023
Annual General Meeting
SQI Diagnostics Inc., Annual General Meeting, Jun 02, 2023

M&A Advisors
Kingsdale Capital Markets Inc., McCarthy Tétrault LLP


Advisors
Most Recent Auditor
RSM & Co
M&A Advisors
Kingsdale Capital Markets Inc., McCarthy Tétrault LLP
Private Placement Advisors
Dundee Capital Corp., Kingsdale Capital Markets Inc., Research Capital Corporation
Public Offering Advisors
Dorsey & Whitney LLP, Gowling WLG International Limited, McCarthy Tétrault LLP, RSM Canada
Key development Advisor
Cantor Fitzgerald, L.P.


Most Recent Auditor
RSM & Co.


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 03:47 AM
SQD
SQI Diagnostics Inc 2023_10_05
Reports
14
MarketLine

Sep 30, 2023 06:01 AM
SQD
SQI Diagnostics Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
289
GlobalData

Sep 15, 2023 10:24 AM
SQD
SQI Diagnostics Inc (SQD.CVE) - Medical Devices Product Pipeline Summary
Reports
63
GlobalData

Sep 08, 2023 12:21 AM
SQD
SQI Diagnostics Inc (SQD.CVE) - Financial Analysis Review
Reports
223
S&P Global Compustat

Sep 07, 2023 03:34 AM
SQD
SQI Diagnostics Inc 2023_09_07
Reports
14
GlobalData

Aug 25, 2023 03:20 AM
SQD
SQI Diagnostics Inc (SQD.CVE) - Medical Equipment - Deals and Alliances Profile
Reports
59
S&P Global Compustat

Jul 06, 2023 03:17 AM
SQD
SQI Diagnostics Inc 2023_07_06
Reports
14
ValuEngine, Inc.

Jul 03, 2023 04:12 AM
SQD
ValuEngine - Toronto Quantitative Stock Report for SQD
Reports
5
MarketLine

Jun 26, 2023 06:01 AM
SQD
SQI Diagnostics Inc.
Reports
29
GlobalData

Jun 14, 2023 01:25 AM
SQD
SQI Diagnostics Inc (SQD.CVE) - Financial Analysis Review
Reports
229


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Connor, Gerald R.

99,774,808

24.50

1.5

May-30-2023


Hanover Group Of Companies Ltd

97,907,714

24.05

1.5

May-30-2023


Matthews, Wilmot Leslie

93,765,129

23.03

1.4

May-30-2023


Marjad Inc.

11,048,978

2.71

0.2

May-30-2023


Cumberland Partners Limited

2,591,318

0.64

0.0

May-30-2023


Next Edge Capital Corp.

1,948,000

0.48

0.0

Jun-30-2023


B.E.S.T. Investment Counsel Limited

364,000

0.09

0.0

Feb-28-2023


Beddoe M.D., Clive J.

40,833

0.01

0.0

May-30-2023


Ricks, Claude 

0

0.00

0.0

Jun-22-2023


Morris, Andrew 

0

0.00

0.0

Jun-05-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Matthews, Wilmot Leslie
93,765,129
168,154

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Ricks, Claude 
0
(1,992,157)
Next Edge Capital Corp.
1,948,000
(575,000)
Marjad Inc.
11,048,978
(553,941)
Connor, Gerald R.
99,774,808
(385,520)
Morris, Andrew 
0
(375,006)
Brouwer Ph.D., Eric 
0
(20,000)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Contract Services, COVID-19 HOME Antibody Test (Future), COVID-19 PCR Testing Kits, Ig_plex Celiac DGP Panel, Ig_plex CHEX Technology, Ig_plex Consumable Assays, Ig_plex Consumable Kits (Future), Ig_plex Microarrays, IgX PLEX Celiac Microarray Test Kit, IgX PLEX Celiac Qualitative Assay, IgX PLEX Rheumatoid Arthritis Qualitative Assay, imaware, QuantiSpot, RALI-Dx (Future), RALI-dx COVID-19 Severity Triage Test (Future), RALI-Dx IL-6 Severity Triage Test (Future), Rali-Dx Systems, RALI-fast (Future), RALI-fast COVID-19 Severity Triage POC Test (Future), Rapid Diagnostic Testing Products, Sqid-X System, SQiDlite, Sqidworks Diagnostics Platform, TORdx LUNG (Future), TORdx LUNG Test, xPlex


Upcoming Events
Date/Time
Type
Jan-26-2024
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Jun-26-2023
-
SQI Diagnostics Inc. (TSXV:SQD)
SEDAR
Notice of the Meeting and Record Date
70 KB
Jun-16-2023
-
SQI Diagnostics Inc. (TSXV:SQD)
SEDAR
News Releases
52 KB
Jun-15-2023
-
SQI Diagnostics Inc. (TSXV:SQD)
SEDAR
Material Change Report
1 MB
Jun-06-2023
-
SQI Diagnostics Inc. (TSXV:SQD)
SEDAR
News Releases
51 KB
Jun-05-2023
-
SQI Diagnostics Inc. (TSXV:SQD)
SEDAR
Management Proxy Materials
73 KB
Jun-05-2023
-
SQI Diagnostics Inc. (TSXV:SQD)
SEDAR
Management Proxy Materials
126 KB
Jun-05-2023
-
SQI Diagnostics Inc. (TSXV:SQD)
SEDAR
Management Proxy Materials
476 KB
May-30-2023
Mar-31-2023
SQI Diagnostics Inc. (TSXV:SQD)
SEDAR
Interim Financial Statements
391 KB
May-30-2023
-
SQI Diagnostics Inc. (TSXV:SQD)
SEDAR
News Releases
59 KB
May-08-2023
-
SQI Diagnostics Inc. (TSXV:SQD)
SEDAR
News Releases
56 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Connor, Gerald R. (Independent Director)
May-19-2023
Common Shares
11,100
-
Derivative Exercise and Retained Stock
0.01
Multiple
Connor, Gerald R. (Independent Director)
May-19-2023
Common Shares
(51,600)
(3,123)
Open Market Disposition
(0.05)
Multiple
Hanover Group Of Companies Ltd
May-19-2023
Common Shares
13,678
-
Derivative Exercise and Retained Stock
0.01
Multiple
Hanover Group Of Companies Ltd
May-19-2023
Common Shares
(51,700)
(3,129)
Open Market Disposition
(0.05)
Multiple
Marjad Inc.
May-19-2023
Common Shares
11,450
-
Derivative Exercise and Retained Stock
0.10
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Beddoe, Clive J.
Independent Chairman of the Board
-
416 674 9500

Ricks, Claude 
Independent Director
-
416 674 9500

Shoenfeld, Yehuda 
Chairman of Scientific Advisory Board
-
416 674 9500

Connor, Gerald R.
Independent Director
+1-416-929-1090
416 674 9500
gerryc@cpwm.ca
Matthews, Wilmot Leslie
Independent Director
-
416 674 9500

Zwisler, Eric 
Independent Director
-
416 674 9500

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Morris, Andrew 
Advisor to the Board & CEO
(229) 416.674.9500
416 674 9500
amorris@sqidiagnostics.com
Lea, Peter
Founder
-
416 674 9500
-
Reddock, Morlan 
CFO & VP of Administration
437-235-6563
416 674 9500
mreddock@sqidiagnostics.com
Brouwer, Eric 
Chief Scientific Officer & Advisor to the Board
416.674.9500 x242
416 674 9500
ebrouwer@sqidiagnostics.com
McGough, Tim 
Chief Commercial Officer
1.401.533.8598
416 674 9500
tmcgough@sqidiagnostics.com
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
